Article

Lymphoma Expert Suggests Asking About Clinical Trials Soon After Diagnosis

Author(s):

Radhakrishnan Ramchandren, M.D.

Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.

Radhakrishnan Ramchandren, M.D., from the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, discusses the role of clinical trials in developing news drugs and standards of care for patients with lymphoma.

In particular, Ramchandren acknowledged that the success from these trials should not be underestimated or underemphasized. In turn, this is why patients should be evaluated for clinical trials and discuss potential eligibility, especially given the landscape of lymphoma, he said.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Related Content
The ADC zilovertamab vedotin plus Rituxan and chemo showed an ORR of 56.3% in relapsed/refractory DLBCL: © stock.adobe.com.
June 9th 2025

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of blood.
June 7th 2025

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

Kristi Rosa
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
June 3rd 2025

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

Linda Cohen
I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.
The phase 1/2 STARLIGHT-1 trial evaluating EB103 has dosed the first patient with advanced B-cell NHL: © stock.adobe.com.
May 30th 2025

First Patient Treated in Second Cohort of STARLIGHT-1 B-Cell NHL Trial

Ryan Scott
The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.